EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 14th, 2020 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations • Kentucky
This exclusive license agreement (“Agreement”) is dated and effective as of the date of last signature (the “Effective Date”) and is made by and between University of Louisville Research Foundation, Inc. (“ULRF”), a Kentucky 501(c)3 non-profit corporation having an office at 300 East Market Street, Suite 300, Louisville, Kentucky, 40202, as the agent of the University of Louisville (“UofL”) for licensing intellectual property owned and controlled by ULRF on behalf of UofL, and Qualigen Therapeutics, Inc. (“Licensee”), a Delaware corporation with a principal place of business at 2042 Corte Del Nogal, Carlsbad, California 92011. ULRF and Licensee are referred to herein, on occasion, separately as a “Party” or together as the “Parties”.
June 23, 2020Qualigen Therapeutics, Inc. • August 14th, 2020 • Pharmaceutical preparations
Re: Letter of Intent by and between Sekisui Diagnostics, LLC (“Sekisui”) and Qualigen, Inc. (“Qualigen”) dated as of March 16, 2018, as amended and restated as of August 22, 2018, as amended (the “LOI”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in the LOI.
May 20, 2020 Attention: David Bocchi Head of Investment Banking New York, NY 10022 Dear David:Qualigen Therapeutics, Inc. • August 14th, 2020 • Pharmaceutical preparations
We refer to the M&A Advisory Agreement (the “Advisory Agreement”), dated October 1, 2019, by and between Ritter Pharmaceuticals, Inc. (the “Company”) and A.G.P./Alliance Global Partners (“A.G.P.”), with respect to A.G.P.’s exclusive engagement as financial advisor to the Company in connection with a possible transaction with the Targets (as defined in the Advisory Agreement). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Advisory Agreement.
